🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Xenon Pharmaceuticals Inc. XENE R2KR3KPHARMA

Healthcare · Biotechnology · Canada
https://www.xenon-pharma.com
Company Profile ↓
$59.75
+58.61% 1Y
Mkt Cap$5.78B
P/E-12.71
P/B8.71
52W High$70.96
52W Low$35.66
Book Value$7.27
EPS (TTM)$-4.70

Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Recent Developments

  • 5-Year Trend Long-term compounding — revenue CAGR -5.7%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-5.70%
1 Year:-

Stock Price Performance

1 Year:+58.61%
6 Months:+42.47%
3 Months:+15.50%
1 Month:-7.44%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 68% of range
$35.66 $70.96
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)42.11 · Neutral
Price Performance
1M-7.44%
3M+15.50%
6M+42.47%
1Y+58.61%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -5.7% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-12.71
Industry PE
25.17
Forward P/E
-11.88
PEG Ratio
-
Book Value
$7.27
Price to Book
8.71
P/S
inf
EV/EBITDA
-12.56
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-5.70%
Profit 5Y
-
Revenue (YoY)
-
Earnings (YoY)
-

Profitability & Returns

ROCE
-63.09%
ROE
-37.53%
ROA
-24.22%
Profit Margin
0.00%
Op Margin
0.00%
Gross Margin
0.00%
EPS (Latest Qtr)
$-1.11
EPS (TTM)
$-4.70

Balance Sheet & Liquidity

Debt/Equity
0.56
Quick Ratio
27.52
Current Ratio
27.79
Debt
$7.49M
Total Assets
$1.30B
Current Assets
$1.11B
Working Capital
$518.86M

Ownership

Promoter Holding
0.11%
Chg in Prom Hold
-0.01%
FII / Inst Holding
107.61%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$5.78B
Total Revenue (TTM)
$0
EBITDA
$-410.19M
Free Cash Flow
$-186.27M
Operating Cash Flow
$-306.36M
Shares Outstanding
96.67M
Gross Margin
0.00%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 XENE Xenon Pharmaceuticals Inc. R2KR3KPHARMA 59.75 -12.71 $5.78B 0.00% -63.09% -37.53% -5.70% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -----------264.00K----------------------7.50M0000-
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ----------------------------------80.24M94.23M96.34M109.77M112.33M-
Operating Income 35.00K-6.14M199.00K-820.00K-2.60M-5.66M-6.37M-7.33M-5.46M-7.99M-7.89M-8.64M-8.05M-7.81M-7.59M-14.19M-11.76M-10.51M-8.95M-8.03M-646.00K-9.70M-16.06M-22.50M-15.60M-17.37M-30.32M-38.13M-49.05M-55.62M-55.68M-59.04M-69.10M-73.68M-72.74M-94.23M-96.34M-109.77M-112.33M-123.16M
EBITDA -----------------------------------72.08M-93.60M-95.69M-109.16M-111.74M-
Interest Expense ----------------------------------------
Pretax Income -----------------------------------64.62M-85.33M-90.22M-104.72M-104.87M-
Tax Provision ----------------------------------427.00K-626.00K677.00K538.00K-2.57M-
Net Income --9.16M1.17M-3.83M-3.94M-3.26M-6.02M-7.71M-6.00M-7.52M-7.38M-7.74M-8.06M-3.75M-7.80M-14.38M-11.34M-10.01M-8.87M-7.48M-175.00K-8.86M-15.76M-22.11M-15.45M-19.67M-31.16M-37.15M-41.73M-47.46M-48.46M-47.93M-57.92M-62.79M-65.05M-84.71M-90.90M-105.26M-102.30M-110.74M
Diluted EPS 0.13-0.64-0.07-0.27-0.27-0.23-0.42-0.51--0.43-0.41-0.43-0.45-0.21-0.45-0.63-0.42-0.37--0.00---0.51-0.36-0.35-0.55-0.57-0.63-0.72-0.73-0.62-0.75-0.81-0.83-1.07-1.15-1.31-1.17-1.11
R&D Expense -3.43M3.67M3.79M-4.36M5.10M5.96M-5.90M6.11M7.16M-5.57M5.42M6.25M9.14M8.21M9.75M11.79M10.72M13.04M16.31M18.38M18.89M19.36M22.15M29.43M39.52M44.04M42.88M44.25M49.70M56.97M61.20M74.98M77.05M-88.51M99.22M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 14.31M27.36M28.37M15.58M1.80M311.00K-6.83M32.17M-9.43M007.50M
Cost of Revenue --------------
Gross Profit --------------
Operating Expenses ----------138.58M214.05M279.30M380.57M
Operating Income -3.15M9.71M11.11M-9.36M-24.82M-32.58M-38.04M-42.82M-31.30M--129.14M-214.05M-279.30M-373.07M
EBITDA -----------127.74M-211.99M-276.74M-370.53M
Interest Expense ---------00---
Pretax Income -----------125.25M-182.69M-238.42M-344.89M
Tax Provision ----------118.00K-292.00K-4.09M1.02M
Net Income -4.30M12.03M13.02M-15.75M-23.00M-30.70M-34.50M-41.59M-28.84M--125.37M-182.39M-234.33M-345.91M
Diluted EPS -3.241.913.28-1.10-1.48-1.72-1.63--0.81--2.06-2.73-3.01-4.36
R&D Expense 10.46M12.30M11.77M15.15M19.83M25.57M23.63M38.84M50.52M75.46M105.77M167.51M210.39M300.94M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --54.49M87.42M63.95M67.49M46.12M122.43M147.70M189.19M-754.15M964.80M798.14M633.16M
Current Assets -----------600.30M644.96M635.26M560.65M
Cash & Equivalents 13.93M60.16M37.95M72.03M58.65M17.09M20.49M67.75M24.75M45.01M-57.24M148.64M142.71M199.16M
Inventory ---------------
Receivables -----------986.00K874.00K1.47M1.37M
Total Liabilities --30.37M14.64M2.92M3.59M10.19M19.13M55.72M17.83M-32.65M36.88M43.24M51.40M
Current Liabilities --18.20M14.29M2.78M3.59M4.08M4.12M43.38M14.78M-22.70M27.27M35.59M41.79M
Long Term Debt ------6.10M15.01M10.89M------
Total Debt -----------10.44M10.90M9.02M7.94M
Total Equity -86.32M-89.86M-78.37M72.78M61.03M63.90M35.93M103.30M91.98M171.35M-721.50M927.92M754.90M581.76M
Shares Outstanding -----------62.59M75.37M76.42M80.01M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ------28.73M-34.72M-4.71M-48.12M--101.03M-151.11M-181.39M-279.12M
Investing Cash Flow -----24.29M-28.99M-66.21M-16.82M--293.40M-111.39M165.00M218.00M
Financing Cash Flow -----7.07M111.59M27.52M85.80M-278.47M353.52M12.13M117.11M
Capital Expenditure -526.00K-156.00K-1.53M-551.00K-279.00K-315.00K-507.00K-1.24M-2.64M--2.89M-5.62M-3.08M-799.00K
Free Cash Flow ------29.04M-35.23M-5.95M-50.76M--103.92M-156.73M-184.46M-279.92M
Net Change in Cash -----------115.96M91.03M-4.26M55.99M

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------
Operating Margin % -22.0%35.5%39.1%-60.1%-1,376.4%-10,474.3%--627.0%-97.3%--1,368.9%---4,974.3%
Net Margin % -30.1%44.0%45.9%-101.1%-1,275.5%-9,872.7%--609.1%-89.7%--1,328.9%---4,612.1%
ROE % 4.8%-15.4%17.9%-25.8%-36.0%-85.4%-33.4%-45.2%-16.8%--17.4%-19.7%-31.0%-59.5%
ROCE % -26.8%15.2%-15.3%-38.8%-77.5%-32.2%-41.0%-17.9%--17.7%-22.8%-36.6%-63.1%

Shareholding Pattern

Insiders
0.11%
Institutions
107.61%
Public Float
107.74%

Top Institutional Holders

#Holder% HeldSharesValue
1 FMR, LLC 9.98% 9.65M $578.78M
2 Blackrock Inc. 7.78% 7.52M $451.27M
3 Avoro Capital Advisors LLC 5.98% 5.78M $346.61M
4 Polar Capital Holdings PLC 4.73% 4.57M $274.19M
5 Driehaus Capital Management, LLC 4.57% 4.42M $265.07M
6 Jupiter Topco LLC 4.33% 4.19M $251.15M
7 Price (T.Rowe) Associates Inc 3.36% 3.25M $194.86M
8 JPMORGAN CHASE & CO 2.71% 2.62M $157.02M
9 Capital International Investors 2.44% 2.36M $141.67M
10 T. Rowe Price Investment Management, Inc. 2.24% 2.17M $130.09M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XENE

Yahoo Finance Fri, 04 Sep 2026

Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care

On August 26, Xenon Pharmaceuticals (NASDAQ:XENE) announced that it will deliver six data presentations at the 16th European Epilepsy Congress in Athens, Greece, running September 5 through 9. The headline slot is an oral presentation of to…

Yahoo Finance Fri, 28 Aug 2026

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, BC and BOSTON, MA, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-cha…

Yahoo Finance Fri, 28 Aug 2026

What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders

Xenon Pharmaceuticals recently announced that it presented multiple new data sets on its lead asset azetukalner at the 16th European Epilepsy Congress in Athens, including topline Phase 3 X‑TOLE2 results in focal onset seizures and long‑ter…

Yahoo Finance Wed, 26 Aug 2026

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

Six presentations planned, including encore oral presentation of topline X-TOLE2 efficacy and safety resultsNew poster will highlight the mechanistic characterization of azetukalner, including its potential additive effects when used with c…

Yahoo Finance hu, 13 Aug 2026

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

Azetukalner advances toward FDA submission as pain pipeline matures.

Yahoo Finance Mon, 10 Aug 2026

Major Depressive Disorder Market is Predicted to Grow During the Forecast Period (2026-2036) as Novel Antidepressants are Expected to Enter the Market | DelveInsight

Recently published Major Depressive Disorder Market Insights report includes a comprehensive understanding of current treatment practices, major depressive disorder emerging drugs, market share of individual therapies, and current and forec…

XENE — Frequently Asked Questions

What is the current share price of Xenon Pharmaceuticals Inc. (XENE)?

As of 2026-09-07 16:24 PDT, Xenon Pharmaceuticals Inc. (XENE) trades at $59.75 on NasdaqGM. Its 52-week range is $35.66 to $70.96.

What is the market capitalisation of XENE?

Xenon Pharmaceuticals Inc. (XENE) has a market capitalisation of $5.78B on NasdaqGM.

What is the P/E ratio of XENE?

XENE trades at a trailing price-to-earnings (P/E) ratio of -12.71. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 8.71.

What is the return on equity (ROE) of XENE?

XENE has a return on equity (ROE) of -37.53%. Its return on capital employed (ROCE) is -63.09%.

Is XENE a good stock to buy?

This page provides a data-driven analysis of Xenon Pharmaceuticals Inc. (XENE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space